Novalis Fund I portfolio company myNEO and CureVac (Nasdaq: CVAC) closed a partnership to identify novel targets for mRNA-based cancer vaccine development.
We’re convinced that combining our tumor characterization and neoantigen target identification methods with an mRNA vaccination technology holds great promise, and believe that CureVac was the logical choice for us to further validate this avenue. Supplementing our own developments with this collaboration will allow us to benefit from CureVac’s years of experience and know-how, and to create a significant impact on the immunotherapy domain.
Read the full press release here:
https://myneo.me/src/Frontend/Files/MediaLibrary/14/20220525-pr-curevac-myneo-deal-en.pdf